A multicenter, dose-finding study to evaluate the safety and efficacy of CNTY-101 in patients with moderate to severe systemic lupus erythematosus (SLE).
Not Yet Recruiting: Trial Expected to Initiate Early in the Third Quarter of 2024
Learn more about Century’s planned Phase 1 clinical trial, CALiPSO-1, with study ID number: NCT06255028 at clinicaltrials.gov.